期刊
CHEMMEDCHEM
卷 6, 期 12, 页码 2273-2286出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201100338
关键词
cancer; drug design; kinase inhibitors; protein kinase CK2; urolithin A
资金
- University of Padova (Italy)
- Italian Ministry for University and Research (MIUR) [protocol: 200834TC4L_002]
Casein kinase 2 (CK2) is a ubiquitous, essential, and highly pleiotropic protein kinase; its abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other relevant diseases. Previously, using different in silico screening approaches, two potent and selective CK2 inhibitors were identified by our group: ellagic acid, a naturally occurring tannic acid derivative (K-i=20 nm) and 3,8-dibromo-7-hydroxy-4-methylchromen-2-one (DBC, K-i=60 nm). Comparing the crystallographic binding modes of both ellagic acid and DBC, an X-ray structure-driven merging approach was taken to design novel CK2 inhibitors with improved target affinity. A urolithin moiety is proposed as a possible bridging scaffold between the two known CK2 inhibitors, ellagic acid and DBC. Optimization of urolithin A as the bridging moiety led to the identification of 4-bromo-3,8-dihydroxy-benzo[c]chromen-6-one as a novel, potent and selective CK2 inhibitor, which shows a K-i value of 7 nm against the protein kinase, representing a significant improvement in affinity for the target compared with the two parent fragments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据